

FORM 51 – 102F3
Material Change Report

Item 1 **Name and Address of Company**

Exro Technologies Inc. (formerly BioDE Ventures Ltd.) (the “Company”)
2820-200 Granville St. Vancouver BC V6C 1S4 E8

Item 2 **Date of Material Change**

August 16, 2017, August 17, 2017 and August 21, 2017.

Item 3 **News Release**

On August 17, 2017 and August 23, 2017 news releases were filed on SEDAR.

Item 4 **Summary of Material Change**

On August 16, 2017, the Company changed its name from BioDE Ventures Ltd. to Exro Technologies Inc. On August 17, 2017, the Company issued a total of 901,100 common shares and approved a private placement of up to 3,000,000 common shares at a price of \$0.20 per common share. On August 21, 2017, the board of directors of the Company approved a share option grant of 3,725,000 options to directors officers and employees of the Company.

Item 5 **Full Description of Material Change**

Name Change

On August 16, 2017, the Company changed its name from BioDE Ventures Ltd. to Exro Technologies Inc.

Private Placement

On August 17, 2017 the board of directors of the Company approved a non-brokered private placement financing (the "Private Placement") of up to 3,000,000 common shares (the "Common Shares", and each a “Common Share”) at a price of \$0.20 per Common Share for gross proceeds of up to CDN\$600,000 (the "Proceeds"). The Proceeds will be used for general working capital and capital reserve. The Private Placement is subject to completion of all definitive documentation and filings as required. The Common Shares issued pursuant to the Private Placement will be subject to a hold period expiring four months plus one day following the date of issuance. The Company will pay a finders’ fee of 7% cash and 7% brokers’ warrants.

Issuance of Shares

On August 17, 2017, the Company has issued a total of 901,100 Common Shares at \$0.20 per share to Intrysync Capital Corporation to satisfy the debt obligations

in the total amount of \$180,220 of the Company and its subsidiary DPM Technologies Inc. The debt was related to finder's fees and consulting fees incurred during the last year in the support of the Company's public listing application.

Share Options

On August 21, 2017, the board of directors of the Company approved the grant of 3,725,000 share purchase options to the directors, officers, employees and consultants of the Company.

All share options are exercisable at \$0.20 per share in accordance with the terms and conditions of the share option plan of the Company. The total number of directors, officers, employees and consultants of the Company who received options pursuant to this grant is 26.

2,679,000 of the options are vested immediately.

75,000 of the options are subject to the following vesting schedule: Options will vest in the following portions after the respective periods of time from the grant date: 1/2 immediately, 1/6 after 12 months, 1/6 after 24 months and 1/6 after 36 months.

971,000 of the options are subject to the following vesting schedule: 1/3 after three months, 2/9 after 12 months, 2/9 after 24 months and 2/9 after 36 months.

The Company's stock option plan was approved by the shareholders at the annual general and special meeting of the Company on December 17, 2015. The number of the common shares which may be issued pursuant to options granted under the plan is 10% of the Issuer's issued and outstanding shares of the Company. As of the date of this material change report, the total number of issued share options is 3,725,000, and the maximum number of share options that can be granted by the Company is 4,309,084.

Item 6 **Reliance on Subsection 7.1 (2) or (3) of National Instrument 51-102**

N/A

Item 7 **Omitted Information**

N/A

Item 8 **Executive Officer**

The following executive officer of the Company is knowledgeable about this report and the material change disclosed herein:

Ann Fehr
Chief Financial Officer

Phone: 604-375-5578

Item 9

Date of Report

August 24, 2017.